Table 2.
Clinical response and dropouts in rheumatoid arthritis and psoriatic arthritis patients treated with etanercept during the follow-up.
| Timing | T14 weeks | T22 weeks | T54 weeks | T102 weeks |
|---|---|---|---|---|
| RA patients (n) | 82 | 81 | 70 | 66 |
| Responders (n/%) | 60/73·2 | 58/71·6 | 49/70 | 43/65·2 |
| No-responders (n/%) | 22/26·8 | 23/28·4 | 21/30 | 23/34·8 |
| Dropouts (n/%) | 1/1·2 | 11/13·6 | 4/5·7 | 8/12·1 |
| PsA patients (n) | 32 | 32 | 29 | 27 |
| Responders (n/%) | 21/65·6 | 21/65·6 | 20/68·9 | 19/70·3 |
| No-responders (n/%) | 11/34·4 | 11/34·4 | 9/31·1 | 9/29·7 |
| Dropouts (n/%) | 0 | 3/9·4 | 2/6·9 | 2/7·4 |
PsA = psoriatic arthritis; RA = rheumatoid arthritis; T = time-point.